---
title: "Rexulti (brexpiprazole), all indications: Dosing and administration questions"
description: "Dosing and administration questions on Rexulti (brexpiprazole) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing and Administration. Questions: How is Rexulti dosed with CYP3A4 or CYP2D6 inhibitors or inducers? Can Rexulti be taken with or without food? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/rexulti/dosing-and-administration"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rexulti (brexpiprazole), all indications: Dosing and administration questions

Manufacturer: Otsuka America Pharmaceutical, Inc.; Lundbeck  
Prescribing information: [Rexulti](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf)  
Indication pages: [Major depressive disorder](https://www.evicenter.com/medical-information/rexulti--major-depressive-disorder)

## Dosing

<a id="rexulti-cyp-dose-adjustments"></a>

### How is Rexulti dosed with CYP3A4 or CYP2D6 inhibitors or inducers?

> “Administer half the dose of REXULTI when taken with strong CYP3A4 inhibitors or in patients who are known CYP2D6 poor metabolizers
> Administer a quarter of the dose with the concurrent use of both strong/moderate CYP2D6 inhibitors and strong/moderate CYP3A4 inhibitors. Likewise, administer a quarter of the dose in patients who are known CYP2D6 poor metabolizers taking strong/moderate CYP3A4 inhibitors
> Double the dose over 1-2 weeks when administering with strong CYP3A4 inducers”

Source: [REXULTI: REXULTI® (brexpiprazole) | MDD | Dosing, captured 2026-11-13](https://www.rexultihcp.com/mdd/dosing#:~:text=Administer%20half%20the%20dose%20of,administering%20with%20strong%20CYP3A4%20inducers)

> “Dosage modifications are recommended in patients who are known cytochrome P450 (CYP) 2D6 poor 
> metabolizers and in patients taking concomitant CYP3A4 inhibitors, CYP2D6 inhibitors, or strong CYP3A4 
> inducers (see Table 1). If the concomitant drug is discontinued, adjust the REXULTI dosage to its original level. 
> If the concomitant CYP3A4 inducer is discontinued, reduce the REXULTI dosage to the original level over 1 to 
> 2 weeks [see Drug Interactions (7.1), Clinical Pharmacology (12.3)].”

Source: [REXULTI: Prescribing information, page 4, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=4)

> “*In the clinical studies examining the use of REXULTI for the adjunctive treatment of MDD, dosage was not adjusted for strong CYP2D6 
> inhibitors (e.g., paroxetine, fluoxetine). Thus, CYP considerations are already factored into general dosing recommendations, and 
> REXULTI may be administered without dosage adjustment in patients with MDD.”

Source: [REXULTI: Prescribing information, page 5, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=5)

## Administration

<a id="rexulti-food"></a>

### Can Rexulti be taken with or without food?

> “Administer REXULTI orally, once daily with or without food [see Clinical Pharmacology (12.3)].”

Source: [REXULTI: Prescribing information, page 3, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=3)

> “REXULTI can be administered with or without food. Administration of a 4 mg REXULTI tablet with a standard 
> high-fat meal did not significantly affect the Cmax or AUC of brexpiprazole.”

Source: [REXULTI: Prescribing information, page 26, captured 2026-11-13](https://www.otsuka-us.com/media/static/Rexulti-PI.pdf#page=26)

## Related pages
- [Medical information: Rexulti (brexpiprazole): All indications](https://www.evicenter.com/medical-information/rexulti)
- [Indication](https://www.evicenter.com/medical-information/rexulti/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/rexulti/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/rexulti/safety)
- [Specific populations](https://www.evicenter.com/medical-information/rexulti/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rexulti/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/rexulti/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rexulti/access-and-coverage)
